GlassScriptPhysician profile
Steven Beljic
NPI 1275627697
$12,484.17
in general payments reported to CMS, 2019-2025
50 companies · $2,003 in 2025
The $2,003 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,552 · 2020: $884 · 2021: $1,684 · 2022: $2,103 · 2023: $2,388 · 2024: $1,871 · 2025: $2,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,224 · Education: $38.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,223.96 |
| Education | $38.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,695.80 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $731.84 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $710.14 | 2019-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $673.93 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $585.33 | 2019-2025 | Xifaxan, Trulance |
| Qol Medical, LLC | $408.37 | 2020-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $389.74 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $353.12 | 2019-2023 | Ocaliva |
| Pfizer INC. | $344.98 | 2019-2025 | |
| Evoke Pharma, INC. | $300.06 | 2020-2025 | Gimoti |
| Gilead Sciences, INC. | $299.94 | 2019-2024 | |
| Vivus LLC | $269.44 | 2019-2025 | Pancreaze |
| Ironwood Pharmaceuticals, INC | $253.62 | 2019-2024 | Linzess |
| Boston Scientific Corporation | $240.95 | 2019-2025 | Axonics |
| Redhill Biopharma INC. | $230.76 | 2020-2022 |
Show all 48 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Beljic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.